Background. Metabolic syndrome (MS) is thought to be a risk marker for cardiovascular diseases in the general population and in patients with chronic kidney disease. This study investigated whether the presence of MS also modifies cardiovascular (CV) outcomes among non-diabetic patients undergoing long-term peritoneal dialysis (PD). Methods. We enrolled 280 patients from a medical centre in North Taiwan who began PD between January 1999 and December 2005 and followed them until December 2009. MS was defined by the modified National Cholesterol Educational Programme (Adult Treatment Panel III) criteria. All parameters and biochemical data were collected by chart review. Patient outcomes (overall and CV death, fatal or non-fatal CV events) were recorded during the follow-up period. Survival was analysed by the Kaplan-Meier method, and the influence of MS and its components on outcomes were analysed by Cox regression models. Results. The average follow-up period was 49.2 months. Non-diabetic patients with MS had worse outcomes than those without MS or at risk for MS, but better than their diabetic counterparts. By multivariate analysis, MS was independently associated with increased risk for CV death (hazard ratio, HR ¼ 13.27) and fatal or non-fatal CV events (HR ¼ 10.50). Among five MS components, hypertriglyceridaemia, low high-density lipoprotein levels and hyperglycaemia were significant risk factors for adverse CV outcomes. Conclusions. MS is a potent risk marker for adverse CV outcomes in non-diabetic patients on PD. Timely interventions targeting specific component of this syndrome may be required in this subset of patients.
Introduction
Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD) and endstage renal disease (ESRD) requiring dialysis therapy [1] . Both traditional and non-traditional risk factors, such as, protein-energy wasting, subclinical inflammation, anaemia and calcium-phosphate product, have been shown to contribute to cardiovascular (CV) complications in patients with CKD [2] [3] [4] . More recently, metabolic syndrome (MS), a constellation of several CV risk factors including central obesity, hypertension, atherogenic dyslipidaemia and hyperglycaemia/insulin resistance [5] , has been linked with the development of CKD [6, 7] ; and its predictive value has been shown for CV outcomes in the general population [8, 9] and in patients with advanced CKD [10] . However, it remains unclear whether the presence of MS also modifies the CV outcomes in non-diabetic patients on maintenance peritoneal dialysis (PD) who are at high risk of developing MS because of chronic exposure to glucose-based solutions [11, 12] . Therefore, this observational study was conducted to investigate the impact of MS and its components on CV morbidity and mortality among a cohort of non-diabetic patients on PD at a single centre in Taiwan.
Materials and methods

Study population
This study was approved by the National Taiwan University Hospital (NTUH) research ethics committee (No. 201005038R). A total of 344 patients who started PD at the NTUH between January 1999 and December 2005 were screened for eligibility. Among those screened, 64 patients were excluded by the following criteria: <18 years of age (n ¼ 7), lack of initial biochemical data (n ¼ 9), failed renal transplant (n ¼ 4) and discontinuation of PD treatment within 3 months (n ¼ 44). The reasons for discontinuation of PD included death (17 patients), shift to haemodialysis (HD) (13 patients), transfer to other hospitals (9 patients), renal transplantation (4 patients) and recovery of renal function (1 patient). Ultimately, a total of 280 patients were enrolled and followed up until December 2009.
Clinical assessment and laboratory measurements
All enrolled patients received conventional glucose-based lactate-buffered PD solutions (Dianeal; Baxter Health Co., Singapore) from the start of PD therapy. Patient-specific data, such as, demographics, underlying renal disease, history of smoking and presence of diabetics and CVD were recorded at the time of enrolment. CVD was defined as ischaemic heart disease, cerebrovascular disease, congestive heart failure or peripheral vascular disease documented in the medical record. Baseline systolic and diastolic blood pressure (BP), dialysis adequacy, residual glomerular filtration rate (GFR) and body mass index (BMI) were measured by standard methods. The number, volume and concentration of glucose exchanges were recorded based on the initial PD regimen and the most commonly prescribed regimen during follow-up. The estimated peritoneal glucose load was calculated by the product of the volume and the glucose concentration of each exchange [11, 13] . Use of any anti-hypertensive drug, statins and fibrates were determined by review of the medical charts.
Biochemical parameters were checked 1 month after the initiation of PD therapy. Fasting venous blood was sampled before the first daily exchange in the morning. Measurements included concentrations of haemoglobin, serum albumin, blood sugar, calcium and phosphorus, triglyceride (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). These biochemical indices were examined regularly at 3-to 6-month intervals in our PD centre. Protein nitrogen appearance rate (PNA) was calculated with validated equations and normalized to actual body weight at baseline. Intact parathyroid hormone was determined by immunoassay, while serum C-reactive protein (CRP) was measured under stable condition to minimize any confounding effect of acute illness.
Definition of MS and its components
MS was defined according to the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) criteria by the presence of at least three following risk factors: (i) systolic BP ! 130 mmHg and/or diastolic BP ! 85 mmHg; (ii) serum TG levels ! 150 mg/dL; (iii) serum HDL-C < 40 mg/dL in men and <50 mg/dL in women; (iv) fasting blood sugar ! 100 mg/dL and (v) central obesity [14, 15] . Because of the possibility of inaccurate measurement of waist circumference in patients on PD, BMI was used to replace this component in the definition of MS. A BMI of >25 kg/m 2 was used to represent 'central obesity' in accordance with the Western Pacific Region of the World Health Organization (WPRO) criteria [16, 17] . This modified criterion has been employed in an Asian-Pacific population of individuals undergoing PD [18] . All enrolled patients were stratified into four groups according to the presence of diabetes and the number of MS components as follows: non-diabetics without MS (0 and 1 component), non-diabetics at risk of MS (2 components), non-diabetics with defined MS (>3 components) and diabetic counterparts. MS was assessed at baseline, typically within 3 months of the start of PD and then before the end of the follow-up period. We evaluated new-onset MS and its components as well as de novo diabetes before the end of the follow-up period. The latter was defined by random plasma glucose level !200 mg/dL or HbA1C !6.5% with/without the use of oral anti-diabetic agents or insulin [19] .
Outcomes and end points
The primary outcomes of this study were death from any cause, CV mortality and first fatal or non-fatal CV events. CV events included ischaemic heart disease (myocardial ischaemia or infarction documented by angiography), sustained arrhythmias (documented by electrocardiography), cerebrovascular events (documented by brain imaging study), peripheral vascular disease (documented by angiographic or sonographic detection of !50% stenosis for the major peripheral arteries of the lower extremities), decompensated heart failure/cardiogenic shock and sudden cardiac death [20] . Sudden cardiac death was defined as unexpected, nontraumatic death within 1 hour from symptom onset and without any previous condition that would appear fatal [21] . The reasons for death and the nature of CV events were documented by the primary care physician. All patients remaining on long-term PD were censored at the end of December 2009 unless they experienced such events as death, shift to HD, kidney transplantation or transfer to other institutions.
Statistical analysis
The data are expressed as means AE SD, medians with interquartile ranges and frequencies with percentages (%) where appropriate. Group differences were assessed by the one-way analysis of variance for normally distributed continuous variables, the Kruskal-Wallis test for non-normally distributed continuous variables and chi-square test for categorical variables. Additionally, Spearman's correlation analysis was conducted to assess the correlations among individual MS components, nutritional parameters, inflammatory marker and estimated peritoneal glucose load. Kaplan-Meier estimate of survival curves and log-rank tests were performed for descriptive analysis of survival data. The events of interest were death from any cause, CV death and first fatal or non-fatal CV event for the analysis of patient survival, CV death-free survival and CV eventfree survival, respectively. Modality shift to HD, kidney transplantation and transfer to another institution were censored observations. The data for a total of 222 non-diabetic patients were included into univariate and multivariate Cox regression models to determine the influence of MS and its components on all-cause mortality and CV outcomes. The patients were further stratified according to the presence or absence of MS, and with or without high CRP level. Those with CRP in the upper half (CRP ! 3.3 mg/L) were defined as having high CRP level (high inflammatory state). Then, the hazard ratios (HRs) of all-cause mortality, CV death and CV events in relation to MS with high CRP level versus non-MS with low CRP level were estimated in Cox regression model. Other relevant traditional and non-traditional CV risk factors were also included in univariate and multivariate analysis. Two-sided P 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS software, version 17.0 (SPSS Inc. Chicago, IL).
Results
Baseline patient characteristics and biochemical parameters
The baseline demographic characteristics and laboratory parameters or indices of the 280 patients are shown in Table 1 . Fifty-eight patients (20.7%) had background diabetes before commencement of long-term PD therapy. Among them, only four patients did not have diabetic nephropathy as their aetiology of renal failure. Other major aetiologies of renal failure included chronic glomerulonephritis (40.7%) and hypertensive nephrosclerosis (10.0%).
The patients were stratified into four subgroups: nondiabetics with no MS, non-diabetics at risk for MS, nondiabetics with defined MS and diabetic counterparts. The detailed comparisons among these four groups are shown in Table 1 . Compared with non-diabetics, patients with diabetes were older and more obese and a higher proportion had a history of smoking and pre-existing CVD. They also had lower levels of HDL-C, serum albumin and normalized PNA (nPNA) and displayed higher levels of fasting blood sugar, CRP and glucose load. Among the non-diabetic group, patients with defined MS were older, more obese and tended to have hypertension and use fibrates for hypertriglyceridaemia. In addition, they also had higher levels of TG, fasting blood sugar and CRP and had lower levels of HDL-C, when compared to patients without MS or at risk for MS.
The correlations among baseline components of MS, nutritional parameters, inflammatory marker and estimated peritoneal glucose load for all participants are shown in Table 2 . The MS components BMI, TG and fasting blood sugar were positively correlated with each other and with CRP level. In contrast, HDL-C level was negatively correlated with other MS components and CRP level. Additionally, CRP level was found to correlate inversely with nPNA and serum albumin. The estimated peritoneal glucose load at baseline was positively correlated with BMI and fasting blood sugar but negatively with serum albumin.
Overall survival, CV death-free survival and CV event-free survival During an average follow-up period of 49.2 months, 77 patients died, 63 patients shifted to HD, 49 patients received renal transplantation and 12 patients were transferred to other institutions. Notably, CVD (49.4%) and infection (40.3%) constituted the most common causes of death. Among the CV deaths, 13 were sudden cardiac deaths, 8 were due to sustained arrhythmias, 6 to ischaemic heart diseases, 4 to decompensated heart failure, 4 to cerebrovascular diseases and 2 to peripheral vascular diseases. Other causes of death included malignancy, intractable gastrointestinal bleeding and liver failure. During the follow-up period, 70 patients developed one or more fatal or non-fatal CV events. The nature of the first CV event was ischaemic heart disease among 24 patients, cerebrovascular disease among 15 patients, sudden cardiac death among 11 patients, arrhythmia among 10 patients and peripheral vascular disease among 10 patients.
Kaplan-Meier survival analysis showed that patients with diabetes were likely to have worse overall rates of survival ( Figure 1A) , CV death-free survival ( Figure 1B ) and fatal or non-fatal CV event-free survival ( Figure 1C) , when compared to non-diabetic patients. Furthermore, nondiabetic patients with defined MS had poorer clinical outcomes than those without MS or at risk for MS.
Univariate analysis of traditional and non-traditional CV risk factors among non-diabetic patients (Table 3) revealed that older age, having a history of smoking, having preexisting CVD, high LDL-C levels, low baseline residual GFR, low baseline nPNA, hypoalbuminaemia and high CRP levels were associated with increased risk of CV morbidity and mortality. Further analysis of individual MS components showed that only hypertriglyceridaemia and hyperglycaemia were significantly associated with adverse CV outcomes.
The unadjusted HRs of MS for all-cause mortality, CV death and CV events were 3.657 (P < 0.001), 4.623 (P ¼ 0.003) and 7.561 (P < 0.001), respectively (Table 4 , Model 1). Compared to non-MS with low CRP level (n ¼ 51), the HRs of MS with high CRP level (n ¼ 86) for all-cause mortality, CV death and CV events were 2.064 (P ¼ 0.003), 2.115 (P ¼ 0.03) and 2.012 (P ¼ 0.004), respectively ( Table 4 , Model 2). When individual MS components as well as other traditional and non-traditional CV risk factors were taken into consideration in multivariate analysis (Table 4 , Model 4), the presence of MS was still independently associated with increased risk for both CV death (HR ¼ 13.27, P ¼ 0.015) and fatal or non-fatal CV event (HR ¼ 10.50, P < 0.001). Other independent risk factors for adverse CV outcomes included pre-existing CVD, history of smoking, low baseline residual GFR, hypoalbuminaemia and high LDL-C level. Regarding individual MS components in multivariate analysis (Table 4 , Model 3), hypertriglyceridaemia, low HDL-C level and hyperglycaemia were significant risk factors for CV morbidity and/or mortality. However, their influences did not reach statistical significance when MS was included in the final analysis (Table 4 , Model 4).
Evolution of MS and its components at the end of follow-up period
The proportions of patients with MS and its components, stratified by sex, at baseline and before the end of follow-up were shown in Table 5 . At the beginning of long-term PD, high BP was most prevalent in patients of both sexes, Fig. 1 . Kaplan-Meier estimates of (A) overall survival rates, (B) CV death-free survival rates and (C) CV event-free survival rates. Patients (n ¼ 280) were stratified into four groups as follows: non-diabetics without MS (n ¼ 54), non-diabetics at risk for MS (n ¼ 78), non-diabetics with MS (n ¼ 90) and diabetic counterparts (n ¼ 58). a Among four groups, b among three groups within non-diabetic patients.
followed by low HDL-C, high TG and high fasting glucose level. Only 10.2% of the men and 9% of the women had a BMI value >25 kg/m 2 . At the end of follow-up, the prevalence of MS increased significantly from 39.8 to 62.5% and 41.0 to 67.2% in males and females, respectively. The prevalence of all five components of MS also increased appreciably during the follow-up. The proportion of patients with high fasting blood sugar increased most conspicuously; and 11 patients (5%) eventually developed de novo diabetes. Furthermore, the estimated peritoneal glucose load, based on the most commonly used PD regimen during follow-up, was positively correlated with BMI (correlation coefficient ¼ 0.190, P ¼ 0.005), TG (correlation coefficient ¼ 0.165, P ¼ 0.015) and fasting blood sugar (correlation coefficient ¼ 0.142, P ¼ 0.035). The correlation between glucose load and the number of MS components was only marginally significant (correlation coefficient ¼ 0.114, P ¼ 0.092).
Discussion
In the present study, we found that MS, defined on the basis of modified NCEP ATP III criteria, was highly prevalent in our long-term PD patients. More importantly, MS was independently associated with increased risk of CV morbidity and mortality among non-diabetic patients. Further analysis of the impact of the individual components of MS revealed that only hypertriglyceridaemia, low HDL-C levels and hyperglycaemia were significant risk factors for adverse CV outcomes.
Previous epidemiologic studies have shown that patients with CKD, especially those undergoing long-term PD, exhibit an increased prevalence of MS [10, 11] . Consistent with these observations, our data revealed that the prevalence of MS in non-diabetic PD patients increased considerably, from 40 to 65%, after an average follow-up period of 4 years. In addition,~5% of our non-diabetic patients developed de novo diabetes, which coincides with the rate reported previously by Szeto et al. [22] . Given the wellknown risk profile of MS for the development of CVD in the general population [8, 9] , it would be critical to know whether MS might adversely affect subsequent CV outcomes in patients undergoing long-term PD. Li et al. first proposed modified ATP III criteria for the definition of MS in Asian PD populations [17] . According to this definition, they found that 53.3% of their patients fulfilled the MS criteria, and those with MS had a worse 8-year CV survival than those without MS. Park et al. [23] also identified MS as a predictor for all-cause mortality in non-diabetic PD patients. Our analysis, based on the same criteria, revealed that non-diabetic patients with MS undergoing PD had better overall survival and CV outcomes than their diabetic counterparts but fared worse than those without MS or at risk for MS. Furthermore, MS was an independent risk marker for CV morbidity and mortality after adjustment for other CV risk factors. In this study conducted in non-diabetic patients undergoing PD, we also found that hypertriglyceridaemia (TG ! 150 mg/dL) was an independent risk factor for adverse CV outcomes. This is reminiscent of the report by Habib et al. [24] , who showed that PD patients who had lower TG levels (<200 mg/dL) had lower all-cause mortality. Furthermore, we noticed that fasting glucose levels >100 mg/dL were associated with poorer patient and CV outcomes, consistent with the results reported by Szeto et al. [22] . Despite these findings, uncertainties remain regarding other aspects of MS for patients on chronic PD [25] [26] [27] [28] . For example, we found that a BMI of 25 kg/m 2 as a cut-off value was not a significant risk factor for adverse CV outcomes. In this study, BMI was used to replace waist circumference, which was not readily measurable in patients on PD. However, the validity of BMI as a surrogate marker for central obesity has never been substantiated on a larger scale [29] . More recent studies employ dual-energy X-ray absorptiometry, bioelectric impedance analysis or abdominal fat computed tomography to measure central obesity or visceral fat mass, which appear to provide better predictions of CV outcomes for patients with ESRD [30, 31] . Additional studies are needed to resolve controversies regarding the central obesity component of MS in the PD population.
In patients undergoing long-term PD, it has been argued that chronic exposure to glucose and its degradation products Table 4 . Multivariate Cox regression analysis of MS and its components as risk factors for all-cause mortality, CV death and fatal or non-fatal CV events in non-diabetic patients on maintenance PD (n ¼ 222) might induce a series of metabolic consequences such as dyslipidaemia, hyperglycaemia, visceral obesity and increased insulin resistance [32, 33] . These derangements could further stimulate oxidative stress and systemic inflammation, leading to endothelial dysfunction, atherosclerosis and, eventually, CV death [34, 35] . Consistent with this notion, we found that patients with greater glucose load during the course of PD therapy had higher BMI, TG and fasting blood sugar, which in turn might increase the prevalence of individual MS component and new-onset MS. Also noteworthy, is that there was a close interlink between MS or its components and inflammatory state. Our nondiabetic patients with defined MS displayed a higher CRP level than those without MS or at risk for MS. In addition, CRP level was positively correlated with BMI, TG and fasting glucose level; while negatively correlated with HDL-C level and nutritional parameters. Further analysis demonstrated that non-diabetic patients with MS and high CRP level had significantly worse CV outcomes than those with non-MS and low CRP level. The interactions between protein-energy wasting, subclinical inflammation and atherosclerotic CV diseases have been well addressed in patients with ESRD. Presumably, uraemic patients with a more profound inflammatory background would be at greater risk of developing malnutrition and CV complications [36, 37] . Taken together, we surmise that the concurrence of these metabolic derangements, along with other sources of systemic and intra-peritoneal inflammation would compromise the nutritional status and associated outcomes in patients on long-term PD [38] .
There are limitations in this study. First, the study design was retrospective in nature, and it was conducted at a single medical centre. Thus, our observations might have been affected by confounding factors and not be generally applicable to patients elsewhere. Second, only a single time point measurement of MS components was used to predict outcomes. Hence, the impact of serial changes in metabolic derangements during PD therapy could not be well assessed. Finally, only one definition of MS was applied in our study, which could not provide a comparison for validation among all the available criteria for MS. Future multicentre prospective cohort studies are needed to evaluate the external validity of this study and to determine the differential impact of the individual components of MS on long-term outcomes.
In conclusion, this observational study shows that MS is independently associated with increased risk of CV morbidity and mortality in non-diabetic patients undergoing long-term PD. It is suggested that PD patients, especially those who are non-diabetic, be monitored for emergence of MS from the outset, and that interventions targeting specific component of this syndrome, especially hypertriglyceridaemia, be given when appropriate to prevent or ameliorate inadvertent CV outcomes.
